We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Algorithm Developed to Predict How and When Proteins Behave Badly

By LabMedica International staff writers
Posted on 05 Mar 2012
Scientists have developed an algorithm that can predict which regions of a protein are susceptible to exposure upon misfolding, and how mutations in the protein and alterations in the cellular environment might affect the stability of these vulnerable regions. More...


The predictions help scientists gain a better determination of protein mechanisms, and may one day help in developing treatments to fight currently lethal neurodegenerative diseases effectively.

Several neurodegenerative diseases--including Alzheimer’s and amyotrophic lateral sclerosis (ALS), recruit and transform healthy proteins to the misfolded form, and amass in large clumps that glue up the processes of the nervous system.

The investigators presented their findings at the 56th annual meeting of the Biophysical Society (BPS), held February 25-29, 2012, in San Diego, CA, USA. The algorithm developed by the researchers utilizes the energy equations of thermodynamics to calculate the likelihood that certain stretches of protein will be displayed when the protein misfolds. Since the exposed regions are specific to the misfolded version of the protein, researchers can use these areas as targets for diagnostic and therapeutic treatments. The algorithm can be modified for different proteins, and it predicts several potential target regions for each protein. The investigators have used it to study neurodegenerative disease-causing proteins as well as misfolded proteins that have been implicated in some cancers.

More recently, the researchers used computer simulations to manipulate proteins in a virtual environment, assessing out how simple it is for mutated proteins to misfold and propagate. Using this application has helped the team predict the progression of hereditary ALS disease. “The fact that we can predict the lifetime of an individual diagnosed with hereditary ALS from simulations of a protein’s mechanical properties is something that is both satisfying and that gives one pause,” said Dr. Steven Plotkin, a biophysicist at the University of British Columbia (Vancouver, Canada) who studies the process of protein misfolding. “We hope that such information might give some clues as to how to develop effective therapies for this disease.”

Related Links:
University of British Columbia
Biophysical Society Annual Meeting


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Immunofluorescence Analyzer
IFA System
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.